Razvan Cristescu
Overview
Explore the profile of Razvan Cristescu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
4744
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dent R, Cortes J, Park Y, Munoz-Couselo E, Kim S, Sohn J, et al.
Breast Cancer Res
. 2025 Mar;
27(1):35.
PMID: 40069763
Background: The multicohort, open-label, phase 1b KEYNOTE-173 study was conducted to investigate pembrolizumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer (TNBC). This exploratory analysis evaluated features of the...
2.
Shao C, Zhou H, Chen C, Dettman E, Ren Y, Cristescu R, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002171
Background/objectives: Mutations in and/or (BRCAm) and other homologous recombination repair genes (HRRm) are associated with several cancers. We evaluated the prevalence and association with overall survival (OS) of somatic BRCAm...
3.
Flechon A, Morales-Barrera R, Powles T, Alva A, Ozguroglu M, Csoszi T, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5353-5364.
PMID: 39475359
Purpose: The three-arm, phase III KEYNOTE-361 study did not meet its dual primary endpoints of progression-free survival (PFS) or overall survival (OS) with first-line pembrolizumab plus chemotherapy versus chemotherapy in...
4.
Chen C, Dettman E, Zhou W, Gozman A, Jin F, Lee L, et al.
Future Oncol
. 2024 Jul;
20(31):2357-2370.
PMID: 39011875
To determine the prevalence of deleterious mutations in and and in 13 genes involved in homologous recombination repair (HRR), the prevalence of genomic loss of heterozygosity and the allelic and...
5.
Zhong W, Ma J, Chen C, Dettman E, Cristescu R, Naik G, et al.
Cancer Med
. 2024 Jun;
13(11):e7358.
PMID: 38864477
Introduction: Hypoxia-inducible factor-2α (HIF-2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC, SDHD, FH, and VHL genes) that are suspected to activate HIF-2α...
6.
Baek M, Chen L, Tekin C, Cristescu R, Jin X, Shao C, et al.
J Gynecol Oncol
. 2024 Jun;
35(6):e105.
PMID: 38857910
Objective: To evaluate the prevalence and prognostic role of programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) in patients with non-immunotherapy-treated advanced cervical cancer. Methods: Clinical data...
7.
Powles T, Chang Y, Yamamoto Y, Munoz J, Reyes-Cosmelli F, Peer A, et al.
Nat Med
. 2024 Jun;
30(9):2508-2516.
PMID: 38823511
Circulating tumor DNA (ctDNA) is emerging as a potential biomarker in early-stage urothelial cancer, but its utility in metastatic disease remains unknown. In the phase 3 KEYNOTE-361 study, pembrolizumab with...
8.
Wehn A, Qiu P, Lunceford J, Yarunin A, Cristescu R, Liu L, et al.
Gynecol Oncol
. 2024 Jan;
184:67-73.
PMID: 38290412
Objective: Authors evaluated the performance of a commercially available next-generation sequencing assay kit; this was based on genomic content from Illumina's TruSight™ Oncology 500 research assay that identifies BRCA variants...
9.
Makker V, Taylor M, Aghajanian C, Cohn A, Brose M, Di Simone C, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38242717
Background: Lenvatinib plus pembrolizumab demonstrated clinically meaningful benefit in patients with previously treated advanced endometrial carcinoma in Study 111/KEYNOTE-146 (NCT02501096). In these exploratory analyses from this study, we evaluated the...
10.
Shao C, Ren Y, Zhou H, Lee L, Chen C, Dettman E, et al.
Adv Ther
. 2024 Jan;
41(2):759-776.
PMID: 38169059
Introduction: Defects in the homologous recombination repair (HRR) pathway can include mutations in BRCA1 and BRCA2 (BRCAm) and other HRR genes (HRRm). These mutations are associated with a homologous recombination...